Empagliflozin alleviates podocytopathy and enhances glomerular nephrin expression in db/db diabetic mice

Figure 6 Volumetric density of nephrin-positive areas and TGF-β-positive areas in glomeruli of nondiabetic db+ and diabetic EMPA-treated and vehicle-treated db/db mice. A: Nephrin-positive areas; B: TGF-β-positive areas. ^aP < 0.001 vs non-diabetic db/+ mice; ^bP < 0.01; ^cP < 0.001 vs vehicle treated db/db mice (Wilcoxon test). Vv: Volumetric density; TGF-β: Transforming growth factor β; EMPA: Empagliflozin.